ProKidney FY2030 Earnings Forecast Reduced by HC Wainwright

ProKidney Corp. (NASDAQ:PROK – Free Report) – Research analysts at HC Wainwright lowered their FY2030 EPS estimates for ProKidney in a report released on Friday, November 13th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of $0.05 for the year, down from their previous forecast of $0.08. The consensus estimate for ProKidney’s current full-year earnings is ($0.51) per share.

Other equities research analysts have also recently issued reports about the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ProKidney in a research report on Tuesday, October 6th. Citigroup dropped their target price on ProKidney to $8.00 and set a “buy” rating on the stock in a report on Wednesday, October 28th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Check Out Our Latest Report on ProKidney

ProKidney Price Performance

Shares of NASDAQ:PROK opened at $1.04 on Monday. ProKidney has a 52 week low of $0.87 and a 52 week high of $2.65. The company’s 50 day moving average is $1.51 and its two-hundred day moving average is $1.76.

ProKidney (NASDAQ:PROK – Get Free Report) last issued its quarterly earnings results on Thursday, November 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). The company had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.12 million.

Insider Buying and Selling

In other ProKidney news, Director Brian Pereira sold 222,949 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $1.44, for a total transaction of $321,046.56. Following the sale, the director owned 222,948 shares of the company’s stock, valued at approximately $321,045.12. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 500,000 shares of company stock valued at $715,000 in the last 90 days. Corporate insiders own 39.83% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Hennion & Walsh Asset Management Inc. raised its stake in ProKidney by 14.6% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 1,847,749 shares of the company’s stock worth $3,769,000 after acquiring an additional 236,056 shares in the last quarter. Renaissance Technologies LLC boosted its stake in ProKidney by 39.6% in the first quarter. Renaissance Technologies LLC now owns 1,250,794 shares of the company’s stock valued at $2,239,000 after acquiring an additional 355,089 shares in the last quarter. Bank of America Corp DE boosted its stake in ProKidney by 6.7% in the first quarter. Bank of America Corp DE now owns 753,412 shares of the company’s stock valued at $1,349,000 after acquiring an additional 47,268 shares in the last quarter. Simplify Asset Management Inc. purchased a new position in shares of ProKidney during the third quarter worth about $803,000. Finally, Amundi grew its holdings in shares of ProKidney by 7.2% during the first quarter. Amundi now owns 291,708 shares of the company’s stock worth $522,000 after purchasing an additional 19,466 shares during the last quarter. 51.59% of the stock is owned by hedge funds and other institutional investors.

About ProKidney

(Get Free Report)

ProKidney is a clinical-stage biotechnology company developing cell therapies for people with chronic kidney disease. The company’s work focuses on treatments intended to help preserve kidney function, particularly in patients with diabetic kidney disease. Its lead investigational product, REACT (REnal Autologous Cell Therapy), is made from cells collected from a patient’s own kidney tissue. The cells are processed and delivered back to the patient’s kidney. REACT is being evaluated in clinical trials and is not an approved treatment.

Recommended Stories

Receive News & Ratings for ProKidney Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProKidney and related companies with MarketBeat.com's FREE daily email newsletter.